Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 6956
Licensor and the Company wish to continue the development and subsequent commercialization of the Flocor Intellectual Property, the Anti-Infectives Intellectual Property and the OptiVax Intellectual Property pursuant to a license to be granted by Licensor to Company.
Patent Rights shall mean all United States or foreign patents or patent applications, and patents to be issued pertaining to Flocor, the Anti-Infectives or Optivax, excluding the use in certain fields; or are divisions, continuations, reissues, renewals, extensions, supplementary protection certificates, utility models and the like of any such United States patents and patent applications and foreign equivalents thereof.
OptiVax shall mean novel polyoxyethylene/polyoxypropylene copolymers that are high molecular weight molecules and are useful as vaccine adjuvants.
Flocor shall mean surface-active copolymers of an ethylene oxide-propylene oxide condensation products that have cytoprotective, rheologic and antithrombotic activities exemplified by poloxamer 188.
Anti-Infectives shall mean polyoxypropylene/polyoxyethylene copolymers and other polyoxyethylene conjugates having therapeutic activity or having the ability to enhance the therapeutic activity of other agents against infective organisms, including bacteria, viruses and fungi.
IPSCIO Record ID: 4279
The Licensee is obligated to pay a royalty on sales under the License for the Flocor Intellectual Property, also on sales under the License for Anti-Infectives Intellectual Property and on sales under the License for OptiVax Intellectual Property.
IPSCIO Record ID: 7755
The term PSMA shall mean all compositions and uses of, collectively molecules that elicit an immune response specific for prostate specific membrane antigen.
The term TranzFect shall mean any polyoxypropylene/polyoxyethylene copolymer compound or compositions or preparations of such compounds claimed in or covered by CytRx Poloxamer Intellectual Property that may be added to Substance to enhance performance of such Substance relative to use of the Substance without Tranzfect.
US PATENT 5,554,372 Methods and vaccines comprising surface-active copolymers
US PATENT 6,086,899 Ethylene oxide-propylene oxide copolymer
US PATENT 5,824,322 Compositions and methods for growth promotion
Licensee will enter research and development activities related to the use of Transfect in the Field, to develop and commercialize a Licensed Product on a commercially reasonable basis.
IPSCIO Record ID: 213335